Charles Craddock, CBE, FRCP, FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the aims and activity of the Trials Acceleration Programme (TAP). This network aims to improve access to cellular therapies and transplantation for hematological malignancies in the UK, and thus improve patient outcomes. As such, the TAP is focused on delivering and accelerating both industry-sponsored and academical clinical trials, as well as investing in specialist research nurses. Prof. Craddock explains that this model is designed to become financially sustainable three years after its launch, and also talks on the important role of the DIDACT foundation in sponsoring clinical trials, redirecting funds towards patients and research nurses, and training the next generation of clinical trials. This project is also an opportunity for UK investigators to collaborate with pharmaceutical companies to accelerate clinical trial delivery. Finally, Prof. Craddock underlines the success of the RECOVERY trial (NCT04381936), which used a novel way of delivering clinical trials. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
